Thermo Fisher Scientific announced the opening of a new Bioprocess Design Center in Hyderabad, India, and the expansion of its existing centers in Incheon, South Korea, and Singapore. The new facility brings state‑of‑the‑art manufacturing equipment and a team of local process engineers to the Indian market, positioning the company to serve the rapidly growing demand for biologics, vaccines, and cell‑and‑gene therapies in the region.
The expansion is part of Thermo Fisher’s broader strategy to deepen its presence in high‑growth markets. Asia’s biopharma sector is projected to grow at a compound annual growth rate of 12% over the next decade, driven by rising healthcare spending, supportive government policies, and increasing investment in advanced therapies. By locating design centers closer to customers, Thermo Fisher can shorten development timelines, reduce shipping costs, and offer more customized process solutions.
“Asia continues to play an increasingly important role in advancing innovation across the global biopharma industry,” said Daniella Cramp, Senior Vice President and President of BioProduction. “By expanding our network in Korea, Singapore and India, we’re bringing world‑class infrastructure and expertise closer to our customers, helping them deliver high‑quality biologics faster, more cost‑effectively and more sustainably.”
The new Hyderabad center will support a portfolio that includes biologics, vaccines, and cell‑and‑gene therapies, while the expanded Incheon and Singapore facilities will enhance capacity for process development, scale‑up, and technology transfer. The move also strengthens Thermo Fisher’s competitive position against rivals such as Lonza and Catalent, who are similarly investing in Asia to capture market share.
Thermo Fisher’s expansion aligns with its recent investments in other Asian markets, including a new manufacturing hub in Shanghai and a joint venture with a leading Korean biotech firm. The company’s focus on local expertise and advanced technology is expected to drive incremental revenue growth in the services segment over the next few years, as more biopharma companies seek end‑to‑end solutions that reduce time‑to‑market.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.